| Market Cap | 33.46M | P/E | - | EPS this Y | 36.30% | Ern Qtrly Grth | - |
| Income | -25.8M | Forward P/E | -1.26 | EPS next Y | 17.20% | 50D Avg Chg | -6.00% |
| Sales | 1.5M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -43.00% |
| Dividend | N/A | Price/Book | 0.64 | EPS next 5Y | - | 52W High Chg | -82.00% |
| Recommedations | 2.50 | Quick Ratio | 1.38 | Shares Outstanding | 13.34M | 52W Low Chg | 7.00% |
| Insider Own | 20.64% | ROA | -15.91% | Shares Float | 84.39K | Beta | 0.78 |
| Inst Own | 86.16% | ROE | -76.26% | Shares Shorted/Prior | 233.14K/178.29K | Price | 4.06 |
| Gross Margin | 33.33% | Profit Margin | - | Avg. Volume | 18,909 | Target Price | 4.06 |
| Oper. Margin | -1,610.83% | Earnings Date | May 9 | Volume | 33,497 | Change | -1.69% |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
| Needham | Buy | Apr 24, 24 |
| Stephens & Co. | Equal-Weight | Apr 17, 24 |
| Benchmark | Speculative Buy | Apr 15, 24 |
| Piper Sandler | Neutral | Nov 13, 23 |
| Needham | Buy | Nov 9, 23 |
| Benchmark | Speculative Buy | Aug 24, 23 |
| Piper Sandler | Neutral | Aug 15, 23 |
| Needham | Buy | Aug 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KINGSLEY ALFRED D | Director Director | Jun 14 | Buy | 0.2149 | 30,000 | 6,447 | 469,111 | 06/15/23 |
| PURA VIDA INVESTMENTS, LLC | 10% Owner 10% Owner | Apr 05 | Buy | 0.3017 | 663,000 | 200,027 | 8,090,202 | 04/07/23 |
| BROADWOOD PARTNERS, L.P. | 10% Owner 10% Owner | Apr 03 | Buy | 0.15 | 26,827,638 | 4,024,146 | 50,181,335 | 04/05/23 |
| KINGSLEY ALFRED D | Director Director | Dec 22 | Buy | 0.285 | 25,000 | 7,125 | 439,111 | 12/27/22 |
| Last Andrew J. | Director Director | Aug 17 | Buy | 0.87 | 20,000 | 17,400 | 70,170 | 08/19/22 |
| Arno Andrew | Director Director | Aug 17 | Buy | 0.9 | 15,000 | 13,500 | 15,000 | 08/19/22 |
| KINGSLEY ALFRED D | Director Director | Aug 15 | Buy | 0.97 | 10,000 | 9,700 | 414,111 | 08/17/22 |
| Gutfreund John Peter | Director Director | Aug 15 | Buy | 0.93 | 25,000 | 23,250 | 25,000 | 08/17/22 |
| GRIFFITH MELINDA | Director Director | Aug 15 | Buy | 1 | 10,000 | 10,000 | 30,000 | 08/17/22 |
| Carter Jennifer L. | Director Director | Aug 15 | Buy | 0.95 | 10,500 | 9,975 | 30,500 | 08/17/22 |
| Arno Andrew | Director Director | Aug 15 | Buy | 0.95 | 150,000 | 142,500 | 282,049 | 08/17/22 |
| PURA VIDA INVESTMENTS, LLC | 10% Owner 10% Owner | Jun 24 | Sell | 1.04 | 99,386 | 103,361 | 8,479,682 | 06/28/22 |
| PURA VIDA INVESTMENTS, LLC | 10% Owner 10% Owner | Apr 14 | Buy | 1.24 | 200,000 | 248,000 | 8,532,663 | 06/28/22 |
| Yu Li | VP Cntrllr/Prncpl Ac.. VP Cntrllr/Prncpl Acctng Offcr | May 18 | Option | 0 | 25,000 | 25,000 | 05/19/22 | |
| Yu Li | VP Cntrllr/Prncpl Ac.. VP Cntrllr/Prncpl Acctng Offcr | May 18 | Sell | 1.14 | 8,128 | 9,266 | 16,872 | 05/19/22 |
| BROADWOOD PARTNERS, L.P. | 10% Owner 10% Owner | Apr 13 | Buy | 0.67 | 6,003,752 | 4,022,514 | 23,353,697 | 04/15/22 |
| Ross Douglas T. | Chief Scientific Off.. Chief Scientific Officer | Mar 25 | Buy | 1.40 | 15,000 | 21,000 | 20,317 | 03/28/22 |
| Paulsen Gisela | Chief Operating Offi.. Chief Operating Officer | Mar 15 | Buy | 1.198 | 16,500 | 19,767 | 16,500 | 03/17/22 |
| ANDREWS RONALD ASBURY | Chief Executive Offi.. Chief Executive Officer | Mar 15 | Buy | 1.283 | 50,000 | 64,150 | 293,212 | 03/17/22 |
| Redmond Cavan M. | Director Director | Mar 16 | Buy | 1.189 | 40,000 | 47,560 | 110,863 | 03/16/22 |
| - | - - | Jan 22 | Buy | 1.71 | 1,460,280 | 2,497,079 | 16,176,484 | 01/22/21 |
| KINGSLEY ALFRED D | Director Director | Dec 28 | Option | 1.34 | 66,508 | 89,121 | 384,111 | 12/28/20 |
| KINGSLEY ALFRED D | Director Director | Dec 28 | Sell | 2.55 | 900 | 2,295 | 318,840 | 12/28/20 |
| KINGSLEY ALFRED D | Director Director | Dec 23 | Option | 1.34 | 58,492 | 78,379 | 326,155 | 12/23/20 |
| KINGSLEY ALFRED D | Director Director | Dec 23 | Sell | 2.54 | 5,148 | 13,076 | 315,639 | 12/23/20 |